Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054363 · ClinicalTrials.gov registry record · Phase 1
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03054363 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 42 participants.
The verdict
NCT03054363, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or second line of therapy in patients with metastatic hormone receptor positive and HER2-positive breast cancer.
Interventions
- DRUG Tucatinib in Combination with Palbociclib and Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2023-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054363
The ClinicalTrials.gov registry entry for NCT03054363 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tucatinib in Combination with Palbociclib and Letrozole is the first listed.
NCT03054363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03054363 about?
NCT03054363 is a clinical study titled "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer". This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or second line of therapy in patients with metastatic hormone receptor po...
What is the current status of trial NCT03054363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-11-27. Estimated completion is 2023-02-07.
What interventions are being tested in trial NCT03054363?
The interventions under investigation include: Tucatinib in Combination with Palbociclib and Letrozole (DRUG).
Who is sponsoring clinical trial NCT03054363?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.